TCGA-LL-A5YL-01A-12R-A29R-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 17
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.290
- KRAS_SIGNALING_DN+0.270
- OXIDATIVE_PHOSPHORYLATION+0.260
- MYOGENESIS+0.250
- PANCREAS_BETA_CELLS+0.250
- ALLOGRAFT_REJECTION+0.240
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.160
- ESTROGEN_RESPONSE_LATE+0.150
- P53_PATHWAY+0.140
- DNA_REPAIR+0.120
Top 10 suppressed
- TGF_BETA_SIGNALING-0.490
- MITOTIC_SPINDLE-0.480
- PROTEIN_SECRETION-0.430
- G2M_CHECKPOINT-0.420
- UV_RESPONSE_DN-0.400
- WNT_BETA_CATENIN_SIGNALING-0.390
- HEME_METABOLISM-0.320
- MTORC1_SIGNALING-0.310
- ANDROGEN_RESPONSE-0.300
- HEDGEHOG_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-S5-A6DX-01A-11R-A31N-07 | — | — | 0.893 |
| 2 | TCGA-E9-A3X8-01A-31R-A22U-07 | — | B | 0.862 |
| 3 | TCGA-AC-A3TM-01A-11R-A22K-07 | — | B | 0.846 |
| 4 | TCGA-OL-A66N-01A-12R-A31O-07 | — | B | 0.836 |
| 5 | TCGA-49-AAR0-01A-21R-A39D-07 | — | cohortA3 | 0.831 |
| 6 | TCGA-85-A4CL-01A-41R-A26W-07 | — | cohortSQ2 | 0.829 |
| 7 | TCGA-LL-A50Y-01A-11R-A266-07 | — | B | 0.824 |
| 8 | TCGA-XF-A8HF-01A-11R-A36F-07 | — | — | 0.823 |
| 9 | MNG431 | — | — | 0.822 |
| 10 | TCGA-V7-A7HQ-01A-11R-A33J-07 | — | B | 0.821 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.240 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.140 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| COMPLEMENT | 0.030 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.020 | Idelalisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |